Skip to main content

Market Overview

The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Biotech stocks see-sawed through the week ended Jan. 31 and ended the month lower overall. Big pharma earnings of the week were mostly disappointing.

Pfizer Inc. (NYSE: PFE) reported disappointing fourth-quarter earnings and Amgen, Inc. (NASDAQ: AMGN) guided 2020 below consensus, while Eli Lilly And Co (NYSE: LLY) managed to outperform expectations.

The week continued to see coronavirus-related spikes, with Cleveland BioLabs, Inc. (NASDAQ: CBLI), NanoViricides, Inc. (NASDAQ: NNVC), Vir Biotechnology, Inc. (NASDAQ: VIR) and Vaccinex, Inc. (NASDAQ: VCNX) among the stocks riding on the momentum.

Acceleron Pharma Inc (NASDAQ: XLRN) was one of the standout gainers of the week, thanks to a positive midstage clinical readout.

The much-anticipated FDA verdict on Aimmune Therapeutics Inc's (NASDAQ: AIMT) peanut allergy drug Palforzia came through in the week, with the regulatory agency greenlighting the drug.

Related Link: 7 Blockbuster Drugs Expected To Be Launched In 2020

Turning ahead to the unfolding week, the following are key catalysts that could create a ripple in the biotech space.


  • 2nd International Scientific & Clinical Congress on Spinal Muscular Atrophy: Feb. 5-7 in Paris, France
  • The European Association for Hemophilia and Allied Disorders, or EAHAD, 2020 Congress: Feb. 5-7 in Hague, Netherlands
  • ASCO-SITC Clinical Immuno-Oncology Symposium: Feb. 6-8 in Orlando, Florida
  • Angiogenesis, Exudation, and Degeneration 2020: Feb. 8 in Miami, Florida

Clinical Readouts

Forty Seven Inc (NASDAQ: FTSV) is due to present at the ASCO-SITC Symposium Phase 1b data for magrolimab + avelumab in ovarian cancer.

Jounce Therapeutics Inc (NASDAQ: JNCE) will present at the ASCO-SITC Symposium Phase 1/2 data for vopratelimab, codenamed JTX-2011, in solid tumors. (Feb. 6)

Catalyst Biosciences Inc (NASDAQ: CBIO) is scheduled to present at the EAHAD Congress Phase 2b data for dalcinonacog alfa in hemophilia B. (Feb. 7)

Kodiak Sciences Inc (NASDAQ: KOD) is due to present at the Angiogenesis, Exudation, and Degeneration 2020with Phase 1b data for KSI-301 in diabetic macular edema (Feb. 8)

Adverum Biotechnologies Inc (NASDAQ: ADVM) will present at the Angiogenesis, Exudation, and Degeneration 2020 with Phase 1 data for ADVM-022 in wet age-related macula degeneration. (Feb. 8)



  • Catalent Inc (NYSE: CTLT) (before the market open)
  • Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (after the close)


  • Zimmer Biomet Holdings Inc (NYSE: ZBH) (before the market open)
  • Haemonetics Corporation (NYSE: HAE) (before the market open)
  • BIO-TECHNE Corp (NASDAQ: TECH) (before the market open)
  • Neurocrine Biosciences, Inc. (NASDAQ: NBIX) (after the close)
  • Gilead Sciences, Inc. (NASDAQ: GILD) (after the close)
  • Qiagen NV (NYSE: QGEN) (after the close)


  • Merck & Co., Inc. (NYSE: MRK) (before the market open)
  • Boston Scientific Corporation (NYSE: BSX) (before the market open)
  • Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) (after the close)
  • Cardiovascular Systems Inc (NASDAQ: CSII) (after the close)
  • Misonix Inc (NASDAQ: MSON) (after the close)
  • SurModics, Inc. (NASDAQ: SRDX) (after the close)


  • ABIOMED, Inc. (NASDAQ: ABMD) (before the market open)
  • Bristol-Myers Squibb Co (NYSE: BMY) (before the market open)
  • Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) (before the market open)
  • Regeneron Pharmaceuticals Inc (NASDAQ: REGN) (before the market open)
  • Twist Bioscience Corp (NASDAQ: TWST) (after the close)
  • Anavex Life Sciences Corp (NASDAQ: AVXL) (after the close)
  • Pacific Biosciences of California (NASDAQ: PACB) (after the close)
  • Enanta Pharmaceuticals Inc (NASDAQ: ENTA) (after the close)
  • Myriad Genetics, Inc. (NASDAQ: MYGN) (after the close)
  • Seattle Genetics, Inc. (NASDAQ: SGEN) (after the close)
  • Natus Medical Inc (NASDAQ: NTUS) (after the close)
  • LeMaitre Vascular Inc (NASDAQ: LMAT) (after the close)
  • Ligand Pharmaceuticals Inc. (NASDAQ: LGND) (after the close)


  • AbbVie Inc (NYSE: ABBV (before the market open)
  • Meridian Bioscience, Inc. (NASDAQ: VIVO (before the market open)


Beam Therapeutics plans to offer 6.25 million shares in an IPO, with the offering expected to be priced between $15 and $17. The company, which is engaged in developing therapies based on single-base gene editing, has applied for listing its shares on the Nasdaq under the ticker symbol "BEAM."

Contract research organization PPD is planning a 60-million-share IPO to be priced in the range of $24-$27. The shares are to be listed on the Nasdaq under the ticker symbol "PPD."


Related Articles (XBI + IBB)

View Comments and Join the Discussion!

Posted-In: CoronavirusBiotech Earnings News Previews Top Stories Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at